The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.

Bayer’s asundexian meets primary efficacy and safety endpoints in landmark phase III OCEANIC-STROKE study in secondary stroke prevention: Berlin Tuesday, November 25, 2025, 11:0 ...

Aanu Adeoye So, Bayer’s drug called asundexian is intended for people who have suffered something called a non-cardioembolic stroke, or people who have suffered a mini stroke, because people who have ...

Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major ...

Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.

Asundexian (Bayer) significantly reduces the risk of ischemic stroke compared with placebo, without increasing the risk of ...

Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges ...

Asundexian is designed to reduce thrombus formation without increasing bleeding risk by selectively inhibiting FXIa.

Once-daily asundexian 50 mg, on top of antiplatelet therapy, reduced risk for recurrent ischemic stroke after a ...

Novo Nordisk’s weight loss drug semaglutide failed to slow the progression of Alzheimer’s disease in two large trials ...

Asundexian’s Phase III win could also bode well for Bristol Myers Squibb, which is also developing a Factor XIa inhibitor called milvexian for stroke prevention, analysts said.